Immune-inflammatory responses and oxidative stress in Alzheimer&apos;s disease therapeutic implications by DI BONA, D. et al.
684 Current Pharmaceutical Design, 2010, 16, 684-691  
 1381-6128/10 $55.00+.00  © 2010 Bentham Science Publishers Ltd. 
Immune-Inflammatory Responses and Oxidative Stress in Alzheimer’s Disease: 
Therapeutic Implications 
D. Di Bona
1
, G. Scapagnini
2
, G. Candore
1
, L. Castiglia
1
, G. Colonna-Romano
1
, G. Duro
3
, D. Nuzzo
3
, F. 
Iemolo
3,4
, D. Lio
1
, M. Pellicanò
1
, V. Scafidi
1,3
, C. Caruso
1,
* and S. Vasto
1
 
1
Immunosenescence Unit, Department of Pathobiology and Biomedical Methodologies, University of Palermo, Italy; 
2
Department of 
Health Sciences, University of Molise, Campobasso, Italy; 
3
IBIM, National Research Council, Palermo; Unit of Neurology, Hospital 
of Vittoria, Ragusa, Italy 
Abstract: Alzheimer's disease (AD) is a heterogeneous and progressive neurodegenerative disease which in Western society mainly 
accounts for clinical dementia. AD has been linked to inflammation and oxidative stress. Neuro-pathological hallmarks are senile 
plaques, resulting from the accumulation of several proteins and an inflammatory reaction around deposits of amyloid, a fibrillar protein, 
A, product of cleavage of a much larger protein, the beta-amyloid precursor protein (APP) and neurofibrillary tangles. Inflammation 
clearly occurs in pathologically vulnerable regions of AD and several inflammatory factors influencing AD development, i.e. 
environmental factors (pro-inflammatory phenotype) and/or genetic factors (pro-inflammatory genotype) have been described. 
Irrespective of the source and mechanisms that lead to the generation of reactive oxygen species, mammalian cells have developed highly 
regulated inducible defence systems, whose cytoprotective functions are essential in terms of cell survival. When appropriately activated, 
each one of these systems has the possibility to restore cellular homeostasis and rebalance redox equilibrium. Increasing evidence support 
the notion that reduction of cellular expression and activity of antioxidant proteins and consequent augment of oxidative stress are 
fundamental causes for ageing processes and neurodegenerative diseases, including AD. The better understanding of different molecular 
and cellular inflammatory mechanisms is crucial for complete knowledge of AD pathophysiology, hence for its prevention and drug 
therapy. Accordingly, two lines of preventive therapeutics can be outlined, the first based on anti-inflammatory drugs, the second one on 
anti-oxidative properties.  
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INTRODUCTION 
 Alzheimer's disease (AD) is a heterogeneous and progressive 
neurodegenerative disease which in Western society mainly 
accounts for clinical dementia. AD has been linked to inflammation 
and oxidative stress. Neuro-pathological hallmarks are senile 
plaques, resulting from the accumulation of several proteins and an 
inflammatory reaction around deposits of amyloid, a fibrillar 
protein, beta-amyloid (A), product of cleavage of a much larger 
protein, the A precursor protein (APP) and neurofibrillary tangles. 
Amyloid deposition, due to the accumulation of A, is the main 
pathogenetic mechanism. Inflammation clearly occurs in patholo-
gically vulnerable regions of AD and several inflammatory factors 
influencing AD development, i.e. environmental factors (pro-
inflammatory phenotype) and/or genetic factors (pro-inflammatory 
genotype) have been described [1-3]. A growing number of studies 
in AD have also reported alterations in systemic immune responses 
including changes in lymphocyte distribution and activation. 
Studies in animal models for AD support the notion that immune 
cells infiltrate the brain and may modulate the disease [4]. 
 On the other hand, irrespective of the source and mechanisms 
that lead to the generation of reactive oxygen species, mammalian 
cells have developed highly regulated inducible defensive systems, 
whose cytoprotective functions are essential in terms of cell sur-
vival. When appropriately activated, each one of these systems has 
the possibility to restore cellular homeostasis and rebalance redox 
equilibrium. Activation of antioxidant pathways is particularly 
important for tissue with relatively weak endogenous antioxidant 
defences, such as the brain. Increasing evidence, in fact, support the 
notion that reduction of cellular expression and activity of anti-
oxidant proteins and consequent augment of oxidative stress play a  
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central role in ageing processes and neurodegenerative diseases, 
including AD [3,5].  
 The better understanding of different molecular and cellular 
immune-inflammatory mechanisms as well as oxidative stress is 
crucial for complete knowledge of AD pathophysiology, and for its 
prevention and drug therapy. 
PATHOPHYSIOLOGY OF AD 
 Amongst the existing entities of dementia spectrums, AD and 
dementia with vascular component are the most prevalent forms of 
dementia. These disorders have common and unique molecular 
pathological characteristics that result in serious reductions in 
nervous-system functionality [6]. AD, the most common cause of 
dementia, accounts for 50 to 70 percent of dementia cases. It is a 
severe neurodegenerative disorder characterized by progressive 
memory and cognitive impairment [7,8]. 
 Under physiological conditions, APP is processed by the non-
amyloidogenic pathway, where cleavage by -secretase releases a 
soluble fragment. In AD, this process is significantly altered, where 
increased amount of APP is cleaved by other endo-proteases such 
as - and -secretase, generating highly amyloidogenic protein 
molecules of 40-42 amino acid residues. Soluble A rapidly 
aggregates into fibrils triggering the misfolding of other A species. 
In vitro studies have shown that extracellular fibrillar A peptides 
induce apoptosis in cultured neurons [9]. The amyloid cascade 
hypothesis is the central hypothesis for the cause of AD, which 
states that the initiating event in AD is an imbalance between the 
production and clearance of A in the brain [10]. Another neuro-
pathological hallmark of AD is the appearance of neurofibrillary 
tangles that consist of a hyperphosphorylated form of the 
microtubule-stabilizing protein tau, often conjugated with ubiquitin. 
The abnormal hyperphosphorylation of tau makes it resistant to 
proteolysis and this might lead to several-fold increase in the levels 
of tau in AD. The hyperphosphorylated tau causes sequestration of 
normal tau and other microtubule-associated proteins, leading to 
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inhibition and disruption of microtubules and impaired axonal 
transport [11]. Tau also becomes prone to aggregation leading to 
formation of intracellular neurofibrillary tangles, compromising 
neuronal and synaptic function.  
 Although the complete etiopathogenesis of AD still remains 
unclear, genetic studies over the past two decades have provided 
valuable insights into this complex and heterogeneous disorder. 
Twin and family studies have shown that certain genes contribute to 
the development of AD, especially with respect to the age at which 
the disease manifests, and more recently, the development of non-
cognitive symptomatology [12]. Early onset familial AD is a very 
rare autosomal dominant disorder caused by highly penetrant 
mutations in APP and presenilin genes, both linked to A 
metabolism. Around twelve different mutations have been 
identified in APP gene at the level of -, -, or -secretase cleavage 
sites, which can lead to alteration in the normal proteolysis of 
amyloid precursor protein. Similarly, more than fifty missense 
mutations of the presenilin-1 gene (PS1) are associated with 
familial AD; several mutations of presinilin-2 gene (PS2) are 
associated with rare cases of early onset familial AD [13]. These 
mutations of APP, PS1 and PS2 may share a common pathogenetic 
mechanism leading to accumulation of -amyloid protein as a result 
of abnormal amyloid precursor protein metabolism. In contrast, 
sporadic AD is a very common disorder. 
 Many studies have reported association of the APOE-4 allele 
with late-onset AD, and APOE-2 has shown a protective effect. 
Moreover, APOE-4 may influence AD pathology by interacting 
with APP metabolism and A protein accumulation, enhancing 
hyperphosphorylation of tau protein and neurofibrillary tangle 
formation, reducing choline acetyltransferase activity, increasing 
oxidative processes, modifying inflammation-related neuroimmu-
notrophic activity and glial activation, altering lipid metabolism, 
lipid transport and membrane biosynthesis in sprouting and 
synaptic remodelling, and inducing neuronal apoptosis [2].  
 Several studies have reported susceptibility loci on chro-
mosome 1, 2, 5, 9, 10, 12, 14, 18, 19 (close to APOE), and 21 
(close to the APP gene) [14]. Other polymorphisms that may also 
be associated with AD are linked to the angiotensin-converting 
enzyme, Cystatin C, tau genes, estrogen receptor [15-18]. Genes 
involved in the neurodevelopmental process have also been 
considered good candidates to confer susceptibility to AD. All these 
genetic factors may interact in unknown genetic networks leading 
to a cascade of pathogenic events characterized by abnormal protein 
folding, with subsequent accumulation of abnormal proteins, 
ubiquitin-proteosome system dysfunction, exicitotoxic reactions, 
oxidative stress, mitochondrial injury, synaptic failure, altered 
metal homeostasis, axonal and dendritic transport dysfunction and 
chaperone misoperation [19,20]. 
IMMUNOLOGY OF AD 
 A deposition plays a key role in AD pathogenesis, indeed it 
causes a chronic inflammatory response which contributes to 
neurodegeneration. The immune response that occurs secondary to 
amyloid deposition in the brain, results in the activation of 
complement cascade and microglial cells, and the recruitment of 
astrocytes [21]. Complement activation contributes to the local 
inflammatory response by the production of inflammatory 
mediators that leads to the migration of activated glial cells towards 
amyloid plaques causing neuronal cell dysfunction and finally 
degeneration [22]. 
 Aggregated amyloid fibrils and inflammatory mediators 
secreted by microglial and astrocytic cells equally contribute to 
neuronal dystrophy. The microglia activation can be due to local or 
systemic inflammation. In fact a strong local inflammatory stimulus 
such as a previous head trauma is a risk factor for AD and several 
epidemiological studies clearly show that blood elevations of acute  
 
phase proteins, markers of systemic inflammatory stimuli, may be 
risk factors for cognitive decline and dementia. Furthermore, in 
experimental animals, chronic systemic inflammatory response 
induced by lipopolysaccharide administration also induces glial 
activation [23].  
 Microglial cells represent 10% of the cells of the adult central 
nervous system (CNS), but following activation they undergo 
morphological and phenotypic changes and differentiate into 
macrophage-like cells. In response to amyloid beta deposition in 
AD, microglial cells express different cells surface receptor and 
they can gain phagocytic or neurotoxic properties with an increased 
production of reactive oxygen species (ROS) [22,24]. The basic 
function of astrocytes is to protect neurons. In the early phase of 
AD there is an astrogliosis that represent a response to the 
accumulation of the amyloid beta in the brain parenchyma and in 
the cerebral microvasculature [25]. Migration of astrocytes to 
amyloid beta plaques is promoted by the chemochines CCL2 and 
CCL3 released by activated microglial cells that surround the 
plaques [26]. There is evidence that indicate an involvement of the 
immune system, other than neuroinflammatory processes in CNS, 
accompanied by changes or defects in immune responses in the 
blood of AD subjects [27]. It is possible that injury signals or 
peptide derived from the AD brain stimulate peripheral immune 
responses. This phenomenon seems to be due to the communication 
between central and systemic immune responses in neuro-
degeneration. There are changes of efflux of CNS proteins, like A, 
or inflammatory mediators, like cytokines and chemokines, across 
the blood-brain-barrier (BBB) that may induce systemic immune 
reaction and the recruitment of lymphocytic or myeloid cells into 
the CNS [4].  
 Concerning T cells, many studies find an increased number of 
these cells in the brain of subjects affected by AD when compared 
with other neurological disease and age-matched controls [28]. The 
BBB consists of endothelial cells with tight junctions, but T cells 
could migrate from blood to brain in AD because peripheral T cells 
of AD patients overexpress MIP-1, which is the ligand of CCR5 
on brain endothelial cells. This interaction promotes T cells 
migration to the endothelial tight junctions [29]. Studies on 
peripheral blood mononuclear cells of AD patients have shown that 
there is an increased expression of the chemokines receptor CCR2 
and CCR5, the chemokine RANTES (CCL5) and the Th1 cytokine 
interferon (IFN)- while MCP-1 chemokine and the Th2 cytokine 
interleukin(IL)-4 are decreased. So chemokines, chemokine recep-
tors and cytokines production are altered not only in the CNS but 
also in the blood cells [27].  
 The molecular and cellular components that mediate the 
communication between peripheral inflammation and the brain 
have been studied in experimental models, and major routes of 
communication are known, all of which lead to the synthesis of 
cytokines and inflammatory mediators in the brain parenchyma, 
which are typically associated with tissue injury [30].  
 Other changes in immune function that occur in AD include an 
altered lymphocyte subpopulation distribution. Richartz-Salzburger 
and collaborators have shown a significant decrease of CD3+ T 
cells and CD19+ B cells, indicating a general decline of immune 
activity in AD. A slight increase of CD4+ Th cells and a decrease 
of the CD8+ CTL without significant change of the CD4+/CD8+ 
ratio. On the contrary CD16+CD56+ NK cells are not altered [31]. 
Recent studies on circulating CD4+ and CD8+ cells demonstrate 
dramatic alteration in naïve and memory subsets of CD4+ lym-
phocytes in AD patients, with an enhanced decrease on percentage 
of naïve CD4+ cells, elevated memory cells and increased 
proportions of CD4+ but not CD8+ cells lacking the costimolatory 
molecule CD28. These data evidence that the immune system of 
AD undergoing persistent antigenic challenge and it could lead to a 
premature immunosenescence [32].  
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 Recently, we reported data on immune-inflammatory para-
meters evaluated in PBMC obtained from AD patients. We showed 
no changes in lymphocytes subsets with the exclusion of B cells 
that are reduced in AD subjects. The study of B cell naïve/memory 
compartment shows a reduction of IgD-CD27- B cells in AD 
patients compared with age-matched healthy controls. Inflam-
matory cytokines IL-1, IL-6, IFN-, tumor necrosis factor(TNF)-, 
chemokines MIP-1 and RANTES as well as chemokines receptors 
CCR2 and CCR5, are up-regulated in AD patients after in vitro 
stimulation with recombinant A peptide. Also CD36, a scavenger 
receptor, is over-expressed in monocytes of AD patients.  
 All together these data confirm the involvement of systemic 
immunity in AD and suggest to continue these kind of study to 
obtain biomarkers useful in the monitoring the effectiveness of 
therapeutics [33]. 
IMMUNE-INFLAMMATORY GENES 
 Variations in immune-inflammatory genes such as cytokine, 
cyclo-oxygenase, lipo-oxygenease, toll-like receptor have also been 
considered to be important in the risk for AD [1,2]. In particular, 
cytokine gene polymorphisms have been claimed to play a key role 
in pathophysiology of AD, as demonstrated by two recent meta-
analysis performed by our group on IL-1 and TNF- [34,35]. 
Therefore, in the present paper, we present data on a meta-analysis 
focused on IL-6. 
 IL-6 is a pleiotropic cytokine involved in the regulation of the 
acute inflammatory response. The expression of IL-6 mRNA 
resulted to be increased in brain areas where amyloid deposition 
and astroglia activation are prominent in AD patients and increased 
IL-6 levels in the brain have been implicated in early stages of 
plaque formation [36].  
 Polymorphisms in the genes regulating the expression of IL-6 
have been hypothesized to enhance the risk of developing AD. In 
particular, the most studied polymorphism of IL-6, the G/C poly-
morphism at the position -174 in the 5’ flanking region of IL-6 
gene, was shown the be associated with a decreased expression and 
also with a reduced plasma level of IL-6 [37]. However, genetic 
association studies, investigating the association with this 
polymorphism and the risk of AD gave very contrasting results. The 
main causes explaining the lack of replicability of the results 
between different studies seems to be the heterogeneity of the 
enrolled study populations, and the small sample size of most 
studies, leading to a loss of statistical power. To overcome some of 
the limitation mentioned above and to increase the relevance of 
statistical analysis a meta-analysis of all available case-control 
studies on the association between IL-6 -174 single nucleotide 
polymorphism (SNP) and the risk of AD have been performed. The 
studies were selected and analysed according to criteria and 
methods discussed in the previous meta-analysis [34,35]. In parti-
cular, the putative risk genotype in homozygosity (GG) was com-
pared to the other two aggregated genotypes data (CG+CC), con-
densing the results into one statistic. This allowed us to highlight 
the effect of the putative risk genotype, as well as to maintain the 
statistical power compared to analyze separately all possible 
transmission models which would have lead to a loss of observation 
and, thus, of statistical power. 
 Sixteen case-control studies on the association between IL-6 -
174 SNP and AD were identified [38-53]. The studies selected 
included a total of 3811 patients and 10716 healthy controls (6303 
of which in the only study of van Oijen et al. [51]). The percentage 
of AD females patients ranged from 58% to 73%, but it was 
missing in the study from van Oien et al. [51,52]. The mean age of 
AD patients ranged from 63,9±10.4 to 80.6±7.8. The sample size of 
the studies varied greatly ranging from 51 to 753, as well as the 
number of controls, ranging from 36 to 6303. Neuropathological 
examination was assessed only in one study [39], the imaging 
examination of the brain to support the clinical diagnosis only in 3 
out of 16 [33,44,50]. Only in three studies [39,44,53] controls were 
selected by mini-mental state examination (MMSE). All studies 
were performed on Caucasian population, except 3, which were 
conducted on Asian population [41]. The effect of the IL-6 -174 
GG genotype on the risk of AD is shown in the Fig. (1).  
 The effect of the TT genotype was to increase the AD risk in 9 
[38-40,42,47-50,52] out of 16 studies, but a statistical significant 
difference was observed in only three [40,48,50]. The pooled 
summary OR was 1.04 (GG vs CG+CC: OR=1.00; 95% C.I.: 0.84-
1.22) and did not achieve statistical significance suggesting that 
subjects with the high producer IL-6 genotype (GG) do not have a 
higher risk of developing AD. There was evidence of heterogeneity 
between the results of individual studies (2=59.20, d.f.=15, 
p=0.00001, I2=73.4%). To reduce heterogeneity and to evaluate 
whether there was a different genotype effect in predefined 
subgroups of studies we performed subgroup analysis in relation to 
patient (age, gender) and study characteristics (type of AD 
diagnosis, MMSE in controls, sample size and statistical power of 
individual studies), but we did not find any difference in the overall 
effect (data not shown).  
 The current meta-analysis summarizes the evidence regarding 
the association between IL-6 -174 SNP and AD, representing a 
pooled total of 3811 cases and 10716 controls. The analysis of 
pooled data ruled out the role of IL-6 -174 SNP in modifying AD 
risk that was hypothesized by some investigators. However, a 
remarkable heterogeneity was observed between the results of 
individual studies, suggesting differences among the enrolled 
populations, and a possible population specific genetic effect of the 
-174 IL-6 SNP. Alternatively, also genetic or environmental factors 
may play a contributing role and may explain differences between 
the result of individual studies. We tried to explain heterogeneity by 
subgroup analysis, taking into account study and patients charac-
teristics, but we fail in identifying variables explaining the observed 
heterogeneity. However, we must consider that we analyzed 
summary results which describe only variation between-study, not 
between patients because they reflect group averages rather than 
individual patient data. Only an individual patient data meta-ana-
lysis could address this issue, but no study reported such detailed 
information, which call for development of publicly available 
databases aimed at the collection and analysis of biologic infor-
mation on a single-patient basis. 
 So, these data do not seemingly support a role for this IL-6 SNP 
in pathophysiology of AD. However, it is to take into account that 
inflammatory mediators do not act alone but they act in a complex 
network reciprocally interacting [54]. Accordingly, we found 
combinations of alleles in eight inflammatory genes (including this 
SNP) and APOE that distinguish AD risk groups [55]. 
OXIDATIVE STRESS 
 Oxidative stress has been implicated in a variety of patho-
physiological conditions, including neurodegenerative disorders, 
and oxidative stress–mediated neuroinflammation has been 
demonstrated to actively concur to AD ethiopathology (extensively 
reviewed [56]). In particular, cortical and hippocampal oxidative 
stress is a very early event in the pathogenesis of sporadic AD and 
correlates with the development of specific cognitive deficits in this 
condition. Inflammation is strictly related to ROS production, 
which act as signals to activate inflammatory genes. Within the cell, 
ROS are physiologically present at minimal concentration as by-
products of aerobic metabolism as well as second messengers in 
many signal transduction pathways and, in normal conditions, there 
is a steady-state balance between pro-oxidants and antioxidants. 
However, when the rate of free radical generation exceeds the 
capacity of antioxidant defences, oxidative stress ensues with 
consequential severe damage to DNA, protein and lipid. One of the 
major sources of ROS production and oxidative stress in AD brain 
is believed to be the impaired mitochondrial electron transport 
Alzheimer’s Diseases and Inflamm-Ageing Current Pharmaceutical Design, 2010, Vol. 16, No. 6    687 
chain. A soluble oligomers, which have been shown to be 
cytotoxic via the formation of ROS, represent another source of 
oxidative stress, as well as the activation of microglial oxidase [57] 
and the inflammatory response [2]. These conditions well explain 
why the biomarkers of lipid peroxidation, such as free 4-
hydroxynonenal (HNE), are abundantly present in several areas of 
the AD brain [58]. Furthermore the presence of carbonylated-, 
HNE- and nitrated-proteins demonstrates the occurrence of protein 
modification by oxidation [59]. Signs of oxidative damage in AD 
patients have also been found in the cerebrospinal fluid, in urine, 
and in serum, and, although the results of some studies are 
contradictory, it seems that the levels of oxidative damage parallels 
the progression of the disease [3].  
 Oxidative stress is counteracted in biological systems by a large 
set of endogenous antioxidants, including enzymes such as 
superoxide dismutases, catalase, and glutathione peroxidase, as well 
as low molecular weight compounds, such as glutathione, generally 
found at levels sufficient enough to defend cells from oxidative 
insult. The brain is particularly low in the antioxidant enzymes, 
particularly those scavenging H2O2, namely glutathione peroxidase 
or catalase. On the other hand mammalian cells have developed 
highly regulated inducible defensive systems that have the 
possibility to restore cellular homeostasis and rebalance redox 
equilibrium [3]. One of the more important system devoted to the 
antioxidant defense in brain is represented by the so called “heat 
shock response” sustained by the “heat shock proteins” (Hsps). 
Among the Hsps family, an emerging role has been attributed to 
heme oxygenase-1 (HO-1 or Hsp-32) which is responsible of the 
transformation of the heme moieties into carbon monoxide and 
biliverdin. All the byproducts of HO-1 activity play a significant 
role in physiological cell functions [60]. In the CNS, the HO system 
has been reported to be very active [61,62] and its modulation 
seems to play a crucial role in the pathogenesis of neuro-
degenerative disorders. Deregulation of the HO system has been 
associated with the pathogenesis of AD, multiple sclerosis and 
brain ageing [63,64]. Many studies clearly demonstrate that 
activation of HO-1 in neurons is strongly protective against 
oxidative damage and cell death [65]. In a very elegant study, 
Panahian et al. using transgenic mice over-expressing HO-1 in 
neurons, demonstrated the neuroprotective effect of this enzyme in 
an experimental model of ischemic brain damage [66]. The 
neuroprotective effects of over-expressed HO-1 can be attributed 
to: (i) increase in cGMP and bcl-2 levels in neurons; (ii) 
inactivation of p53, a protein involved in promoting cell death; (iii) 
increase in antioxidant sources and (iv) increase in the iron 
sequestering protein, ferritin [66]. Particularly interesting is the role 
played by HO-1 in AD. Significant increases in the levels of HO-1 
have been observed in AD brains in association with neurofibrillary 
tangles and also HO-1 mRNA was found increased in AD 
neocortex and cerebral vessels [63,67]. HO-1 increase was not only 
in association with neurofibrillary tangles, but also co-localized 
with senile plaques and glial fibrillary acidic protein-positive 
astrocytes in AD brains [68]. In addition Takeda et al. explored the 
relationship between HO-1 and tau protein, this latter being the 
major component of neurofibrillary tangles, the intraneuronal AD 
lesion. In transfected neuroblastoma cells overexpressing HO-1, the 
activity of this enzyme was increased, and conversely, the level of 
tau protein was significantly decreased when compared with 
antisense HO-1 or vector transfected cells [63]. The suppression of 
tau protein expression was almost completely counteracted by zinc-
deuteroporphyrin, a specific inhibitor of HO activity [63]. Thus 
HO-1 is thought to down regulate the production of tau and recently 
HO-1 polymorphisms have been considered as a possible respon-
sible for susceptibility to AD [69]. Thus, modulation of HO-1 
should represent a potential pharmaceutical strategy for the treat-
ment of neurodegenerative disorders [70].  
 The role of smoking in AD has been debated [71]. In the last 
years, several case-control studies suggested that smoking was 
associated with decreased risk of dementia [72,73]. On the other 
hand, it has been hypothesized that findings obtained in case-
control studies were a consequence of survival bias rather than a 
true protective effect of smoking [74]. However, the mechanisms 
by which smoking would prevent the risk of AD should be related 
to the positive nicotinic effects of smoking on cognitive functioning 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Meta-analysis of 16 case-control studies of the IL-6 -174 polymorphism and the risk for AD using the random-effects model. Odds Ratio (OD) 
for each study and the pooled estimate of the OD for the risk of AD with its Confidence Interval (CI) are plotted on the graph. Studies are arranged 
chronologically based on the year of publication. 
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[72,75]. On the other hand, the increased frequency of cardio-
vascular and cerebrovascular illnesses among smokers [71] is likely 
to increase the risk of AD in later life [76,77]. However, the results 
of a recent meta-analysis of prospective studies clearly showed that, 
when compared with people who have never smoked, current 
smokers have an increased risk of dementia and cognitive decline 
ranging from 40 percent to 80 percent, depending on the outcome 
examined [73]. Oxidative stress is a possible mechanism consistent 
with dangerous effects of smoking since cigarette smoke contains 
free radicals that activate inflammatory cells with inflammatory 
mediator production and further oxidative damage by triggering a 
vicious cycle [2,71]. 
CONCLUSIONS 
 A major goal of ongoing research in AD is to improve early 
detection by developing tools to move diagnosis backward in 
disease temporal course, i.e. before the clinical manifestation of the 
disease, where a treatment might play a decisive role in preventing 
or significantly retarding the manifestation of the disease [1,2]. So, 
the knowledge of the pathophysiology of the diseases is crucial for 
its therapeutic prevention. Accordingly to the data discussed in the 
present review, two lines of preventive therapeutics can be 
discussed, the first based on anti-inflammatory drugs, the second 
one on anti-oxidative properties. 
 Concerning anti-inflammatory drugs, patients who received 
non-steroidal anti-inflammatory drugs (NSAIDs) for a period of 2 
years had less AD incidence with relative risk of 0.2 [78]. The 
incidence of AD appears to be reduced in some post hoc studies, by 
about 13%for aspirin and 28% for other NSAIDs [79-81]. However, 
a recent report based on a longitudinal study of men and women 
aged 70 years and older with a family history of AD (ADAPT 
study) showed that use of naproxen or celecoxib did not improve 
cognitive function [82]. However, several critical issues have been 
raised concerning the study results, i.e. it has been claimed that the 
ADAPT study does not indicate that NSAIDs, if taken during 
adulthood and for an extended period, cannot prevent or delay the 
onset of dementia [83]. In addition, examining the effects on AD 
risk of NSAID use for >5 years in a large health care database 
including 49,349 cases and 196,850 controls, Vlad et al. clearly 
demonstrated that long-term NSAID use was protective against AD 
[84]. 
 Regarding molecules with anti-oxidant properties, a number of 
experimental and epidemiological studies have recently supported 
the beneficial effects of some commonly used natural products in 
preventing various pathologic conditions ranging from cardio-
vascular diseases to cancer. Spices and herbs often contain phenolic 
substances with potent antioxidative and chemopreventive 
properties [85]. However, since curcumin studies are a growing 
area in AD research as well as in other pathological conditions 
[86,87], we will insight into its possible effect on AD. 
 Curcumin (1,7-bis[4-Hydroxy-3-methoxyphenyl]-1,6-hepta-
diene-3,5-dione), a colouring agent and food additive commonly 
used in Indian culinary preparations extracted from the rhizome of 
Curcuma Longa, polyphenolic substance has the potential to inhibit 
lipid peroxidation and to effectively intercept and neutralize ROS 
[70]. Curcumin has been shown to significantly increase HO-1 
expression and activity in vascular endothelial cells [88], in rat 
astrocytes [89] and in cultured hippocampal neurons [90]. This 
latter effect on HO-1 can explain, at least in part, the strong anti-
oxidant and anti-inflammatory properties of curcumin, that depends 
more by its action as cellular signals than by its radical scavenger 
effect [70]. Curcumin has been demonstrated to stimulate the 
mitogen-activated protein kinase pathway and to activate 
heterodimers of NF-E2-related factors 2, leading to induction of the 
antioxidant responsive element activated reporter genes [91]. By 
this pathways curcumin strongly induce the expression of phase II 
detoxification enzymes and of HO-1, resulting in cell protection 
and enhancing cell survival [90]. The involvement of curcumin in 
restoring cellular homeostasis and rebalancing redox equilibrium, 
suggests that it might be a useful adjunct also in AD treatment. 
Epidemiological studies suggested that curcumin, as one of the 
most prevalent nutritional and medicinal compounds used by the 
Indian population, is responsible for the significantly reduced (4.4-
fold) prevalence of AD in India compared to United States [92]. 
Furthermore, Elderly Singaporeans who ate curry with turmeric had 
higher MMSE scores than those who did not [93]. However, the 
relatively short duration of follow-up, cultural factors and other 
potential confounders suggest caution in interpreting these findings. 
Consistent with these data, Lim and colleagues have provided 
convincing evidence that dietary curcumin, given to an Alzheimer 
transgenic mouse model (Tg2576) for 6 months, resulted in a 
suppression of indices of inflammation and oxidative damage in the 
brain of these mice and to reverse A-induced cognitive deficits 
[94,95]. The same group demonstrated in a successive research that 
curcumin was a better A40 aggregation inhibitor than ibuprofen 
and naproxen, and prevented A42 oligomer formation and toxicity 
at very low concentration (between 0.1 and 1.0 microM) [96]. They 
also shown that curcumin readily entered the brain to label plaques 
in vivo inhibiting the formation of A oligomers and their toxicity 
[96]. Among the several mechanisms by which curcumin is able to 
clear amyloid is the induction of HSPs, that function as molecular 
chaperones to block protein aggregate formation [97]. Recently 
curcumin has been evaluate in a pilot clinical trial in AD patients, 
with preliminary encouraging results [98]. Curcumin is highly 
lipophilic and might cross the BBB and reach the brain, and 
although its bioavailability is very low, since the drug is rapidly 
metabolized by conjugation, curcumin may reach brain concen-
trations sufficient to activate signal transduction events and to 
decrease A aggregation [99]. Other plant-derived phenolic agents 
with analogous chemical structures to curcumin have been 
demonstrated to strongly activate HO-1 expression and to defend 
cells against oxidative stress. In particular, ethyl ferulate, 
resveratrol (a phitoalexin derived from grape) and caffeic acid 
phenethyl ester, are able to protect neurons via HO-1 induction 
[100]. These and other studies identify a novel class of natural 
substances that could be used for therapeutic purposes as potent 
inducers of HO-1 in the protection of tissues against inflammatory 
and neurodegenerative conditions. It needs to be emphasized that 
curcumin, and other plant constituents eventually become part of 
the human diet and can be consumed daily as herbal supplements. 
Further in vitro and in vivo studies using curcumin-like molecules 
will give important information on the feasibility of developing new 
pharmacological strategies for maximizing heme oxygenase activity 
in targeted tissues as an alternative to or in combination with HO-1 
gene therapy.  
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